[
  {
    "ts": null,
    "headline": "Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?",
    "summary": "INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.",
    "url": "https://finnhub.io/api/news?id=199d96a4c2cc628ad220db91a6e2d42c2ddd10aa9a7ae393554318f550bf118a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761314220,
      "headline": "Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?",
      "id": 137215924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.",
      "url": "https://finnhub.io/api/news?id=199d96a4c2cc628ad220db91a6e2d42c2ddd10aa9a7ae393554318f550bf118a"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=1559629931fb2aaf5498b685d75b71e184b82b3744e0186ee0b9db8cf895ec30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761310804,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 137218535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=1559629931fb2aaf5498b685d75b71e184b82b3744e0186ee0b9db8cf895ec30"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial",
    "summary": "New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. These 52-week results from the BRAVE-AA-PEDS trial – the largest Phase 3 study of its kind – will be presented at the 2025 Fall Clinical Dermatology (FCD) Conference, taking place Oct. 23-26 in Las Vegas.1",
    "url": "https://finnhub.io/api/news?id=05690680a4cc32dce58fad8a3496424229d2cf8cae87d01e63f561983d77f2f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761302700,
      "headline": "Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial",
      "id": 137215931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. These 52-week results from the BRAVE-AA-PEDS trial – the largest Phase 3 study of its kind – will be presented at the 2025 Fall Clinical Dermatology (FCD) Conference, taking place Oct. 23-26 in Las Vegas.1",
      "url": "https://finnhub.io/api/news?id=05690680a4cc32dce58fad8a3496424229d2cf8cae87d01e63f561983d77f2f6"
    }
  }
]